BR0015307A - Composto, composição, composição farmacêutica, métodos para tratar um distúrbio que é criado pela ou é dependente da disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, e para inibir a absorção de norepinefrina sináptica, de serotonina sináptica e de dopamina sináptica em um paciente em necessidade destas, e, conjunto - Google Patents
Composto, composição, composição farmacêutica, métodos para tratar um distúrbio que é criado pela ou é dependente da disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, e para inibir a absorção de norepinefrina sináptica, de serotonina sináptica e de dopamina sináptica em um paciente em necessidade destas, e, conjuntoInfo
- Publication number
- BR0015307A BR0015307A BR0015307-9A BR0015307A BR0015307A BR 0015307 A BR0015307 A BR 0015307A BR 0015307 A BR0015307 A BR 0015307A BR 0015307 A BR0015307 A BR 0015307A
- Authority
- BR
- Brazil
- Prior art keywords
- synaptic
- serotonin
- norepinephrine
- dopamine
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16327099P | 1999-11-03 | 1999-11-03 | |
PCT/US2000/030328 WO2001032624A1 (fr) | 1999-11-03 | 2000-11-03 | Tetrahydroisoquinolines a substitution 4-phenyle et utilisation de ces dernieres pour bloquer le recaptage de la norepinephrine, de la dopamine et de la serotonine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0015307A true BR0015307A (pt) | 2002-07-09 |
Family
ID=22589231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0015307-9A BR0015307A (pt) | 1999-11-03 | 2000-11-03 | Composto, composição, composição farmacêutica, métodos para tratar um distúrbio que é criado pela ou é dependente da disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, e para inibir a absorção de norepinefrina sináptica, de serotonina sináptica e de dopamina sináptica em um paciente em necessidade destas, e, conjunto |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1246805A1 (fr) |
JP (1) | JP4907817B2 (fr) |
KR (2) | KR100878855B1 (fr) |
CN (1) | CN100436420C (fr) |
AU (1) | AU784280B2 (fr) |
BR (1) | BR0015307A (fr) |
CA (1) | CA2389300C (fr) |
MX (1) | MXPA02004329A (fr) |
NZ (1) | NZ519146A (fr) |
RU (1) | RU2293728C2 (fr) |
WO (1) | WO2001032624A1 (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
EP1246806B1 (fr) * | 1999-11-03 | 2008-02-27 | AMR Technology, Inc. | Tetrahydroisoquinolines a substitution aryle et heteroaryle et utilisation de ces composes pour bloquer le recaptage de norepinephrine, de dopamine et de serotonine |
ES2299561T3 (es) | 2001-01-26 | 2008-06-01 | Btg International Limited | Analogo de bencilamina. |
US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
DE10154689A1 (de) * | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
US6844316B2 (en) | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
CN100497314C (zh) * | 2001-12-05 | 2009-06-10 | 塞诺菲-安万特德国有限公司 | 取代的4-苯基四氢异喹啉、其制备方法、其用作药物的用途以及含有它们的药物 |
US6911453B2 (en) | 2001-12-05 | 2005-06-28 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them |
US6703405B2 (en) | 2001-12-22 | 2004-03-09 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them |
WO2004050630A1 (fr) * | 2002-12-02 | 2004-06-17 | Pharmacia & Upjohn Company Llc | Utilisation de tetrahydroisoquinoleines a substitution dans le traitement de douleurs chroniques et neuropathiques, de cephalee migraineuse et de l'incontinence urinaire par imperiosite, d'effort et mixte |
BR0316837A (pt) * | 2002-12-02 | 2005-10-18 | Pharmacia & Upjohn Co Llc | Utilização de tetrahidroisoquinolinas 4-fenil substituìdas no tratamento da dor, enxaqueca e incontinência urinária |
MXPA05005829A (es) * | 2002-12-02 | 2005-08-29 | Pharmacia & Upjohn Co Llc | El uso de tetrahidroisoquinolinas 4-fenil-sustituidas en el tratamiento del dolor, dolores de cabeza migranosos e incontinencia urinaria. |
US7241775B2 (en) | 2003-03-24 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines |
DE10312963A1 (de) * | 2003-03-24 | 2004-10-07 | Aventis Pharma Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
DE602004026712D1 (de) | 2003-05-05 | 2010-06-02 | Probiodrug Ag | Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen |
MXPA06003998A (es) | 2003-10-15 | 2006-06-27 | Probiodrug Ag | Uso de efectores de ciclasas de glutamato y glutaminil. |
KR101389246B1 (ko) * | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
DE102004046492A1 (de) | 2004-09-23 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
US20060111394A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
US20060111393A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
US20060194837A1 (en) * | 2004-12-17 | 2006-08-31 | Carruthers Nicholas I | Tetrahydroisoquinoline compounds |
DE102005001411A1 (de) | 2005-01-12 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
FR2884251B1 (fr) * | 2005-04-08 | 2007-07-13 | Servier Lab | Derives de piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CN101243083A (zh) | 2005-06-17 | 2008-08-13 | 詹森药业有限公司 | 萘啶化合物 |
CN101243082A (zh) | 2005-06-17 | 2008-08-13 | 詹森药业有限公司 | 治疗cns障碍的六氢-吡咯并-异喹啉化合物 |
KR101594898B1 (ko) | 2005-07-15 | 2016-02-18 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
CA2621836C (fr) * | 2005-09-09 | 2013-11-12 | Analytecon Sa | Isoquinolines utilises en tant qu'inhibiteurs d'igf-1r |
DE102005044815A1 (de) * | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung |
CN100386319C (zh) * | 2005-12-05 | 2008-05-07 | 中国人民解放军第二军医大学 | 具有抗生育和抗真菌活性的四氢异喹啉类化合物或其盐类 |
BRPI0712429A2 (pt) * | 2006-05-31 | 2014-03-11 | Hoffmann La Roche | Derivados de benzazepina como inibidores de re-captação de monoamina |
WO2008144305A1 (fr) * | 2007-05-18 | 2008-11-27 | Janssen Pharmaceutica N.V. | Tétrahydroisoquinolines diaryl-substituées utilisables en tant que modulateurs du récepteur h3 de l'histamine et du transporteur de la sérotonine |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
EA020553B1 (ru) * | 2009-05-12 | 2014-12-30 | Олбани Молекьюлар Рисерч, Инк. | 7-([1,2,4]ТРИАЗОЛО[1,5-α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИЧЕСКИХ РАССТРОЙСТВ |
JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用 |
WO2010132437A1 (fr) | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryle, hétéroaryle et tétrahydroisoquinolines à hétérocycle substitué et leur utilisation |
EP2420237A1 (fr) * | 2010-08-11 | 2012-02-22 | Ville Takio | Dérivés fluorés d'isoquinoléines endogènes pour leur utilisation dans le traitement de maladies liées aux passages d'isoquinoline endogène |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3666763A (en) * | 1970-01-06 | 1972-05-30 | Hoffmann La Roche | 4-phenyl isoquinolines and process for preparing same |
US3947456A (en) * | 1970-01-06 | 1976-03-30 | Hoffman-La Roche Inc. | Substituted 4-phenyl isoquinolines |
CH538477A (de) * | 1970-01-06 | 1973-06-30 | Hoffmann La Roche | Verfahren zur Herstellung von Isochinolin-Derivaten |
GB1504424A (en) * | 1975-08-09 | 1978-03-22 | Beecham Group Ltd | Isoquinoline-derived aminoethers |
US4340600A (en) * | 1980-05-22 | 1982-07-20 | Smithkline Corporation | Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines |
BG49761A1 (en) * | 1989-04-24 | 1992-02-14 | Vissh Khim T I | 4- (4'- chalophenyl)- 2- methyl- 1, 2, 3, 4- tetrahydroisohinolines and method for its preparation |
US5607939A (en) * | 1994-04-28 | 1997-03-04 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
EP1246806B1 (fr) * | 1999-11-03 | 2008-02-27 | AMR Technology, Inc. | Tetrahydroisoquinolines a substitution aryle et heteroaryle et utilisation de ces composes pour bloquer le recaptage de norepinephrine, de dopamine et de serotonine |
-
2000
- 2000-11-03 EP EP00976884A patent/EP1246805A1/fr not_active Withdrawn
- 2000-11-03 CN CNB008177899A patent/CN100436420C/zh not_active Expired - Fee Related
- 2000-11-03 KR KR1020027005740A patent/KR100878855B1/ko not_active IP Right Cessation
- 2000-11-03 CA CA2389300A patent/CA2389300C/fr not_active Expired - Fee Related
- 2000-11-03 MX MXPA02004329A patent/MXPA02004329A/es active IP Right Grant
- 2000-11-03 WO PCT/US2000/030328 patent/WO2001032624A1/fr active IP Right Grant
- 2000-11-03 BR BR0015307-9A patent/BR0015307A/pt not_active IP Right Cessation
- 2000-11-03 NZ NZ519146A patent/NZ519146A/en not_active IP Right Cessation
- 2000-11-03 RU RU2002114337/04A patent/RU2293728C2/ru not_active IP Right Cessation
- 2000-11-03 JP JP2001534776A patent/JP4907817B2/ja not_active Expired - Fee Related
- 2000-11-03 KR KR1020087015487A patent/KR20080065707A/ko not_active Application Discontinuation
- 2000-11-03 AU AU14596/01A patent/AU784280B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CA2389300A1 (fr) | 2001-05-10 |
KR20080065707A (ko) | 2008-07-14 |
KR100878855B1 (ko) | 2009-01-15 |
CA2389300C (fr) | 2010-06-08 |
RU2293728C2 (ru) | 2007-02-20 |
JP4907817B2 (ja) | 2012-04-04 |
AU1459601A (en) | 2001-05-14 |
JP2004501860A (ja) | 2004-01-22 |
EP1246805A1 (fr) | 2002-10-09 |
AU784280B2 (en) | 2006-03-02 |
KR20020081211A (ko) | 2002-10-26 |
CN100436420C (zh) | 2008-11-26 |
NZ519146A (en) | 2004-02-27 |
CN1413197A (zh) | 2003-04-23 |
WO2001032624A1 (fr) | 2001-05-10 |
MXPA02004329A (es) | 2005-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0015307A (pt) | Composto, composição, composição farmacêutica, métodos para tratar um distúrbio que é criado pela ou é dependente da disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, e para inibir a absorção de norepinefrina sináptica, de serotonina sináptica e de dopamina sináptica em um paciente em necessidade destas, e, conjunto | |
BR9814087A (pt) | Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente | |
RU94044671A (ru) | Применение непептидных антагонистов рецептора тахикинина | |
WO2001001973A8 (fr) | Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation | |
BR0214967A (pt) | Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente | |
BR9909277A (pt) | Compostos com atividade em receptores muscarìnicos | |
BR9808281A (pt) | Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto | |
BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
BR0112093A (pt) | Derivados de sulfonil-pirrolidina úteis no tratamento de distúrbios neurológicos | |
BR9810712A (pt) | Processo para a prevenção ou tratamento de prurido em um paciente | |
GEP19960656B (en) | Method for production of phenylalkylamines or its pharmaceutically acceptable salts | |
BR0215801A (pt) | Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos | |
BRPI0307351B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto | |
BR9810592A (pt) | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto | |
PA8493701A1 (es) | Compuestos para tratar la obesidad | |
BRPI0518000A (pt) | tetrahidroisoquinolinas aril- e heteroaril- substituìdas e uso das mesmas para bloquear a reabsorção de norepinefrina, dopamina e serotonina | |
BR9708815A (pt) | Composições farmacêuticas para prevenção e tratamento de desordens do sistema nervoso central. | |
BR0112476A (pt) | Uso de agonistas do receptor d2/d3 de dopamina para tratar fibromialgia | |
BR0313624A (pt) | Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória | |
ATE128622T1 (de) | Behandlungsmittel. | |
PT911331E (pt) | Compostos de dibenzoxazepina substituidos composicoes farmaceuticas e metodos de utilizacao | |
DE69935670D1 (de) | Behandlung von dyskinesie durch mu-selektive opioidantagonisten | |
BR0011578A (pt) | Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico | |
PT1194415E (pt) | Novos derivados da piperazinil-alquil-tiopirimidina composicoes farmaceuticas que os contem e um processo de preparacao da substancia activa | |
NO20014241D0 (no) | C16-umettede FP-selektive prostaglandinanaloger |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: AMR TECHNOLOGY, INC. (US) Free format text: TRANSFERIDO DE: ALBANY MOLECULAR RESEARCH, INC. |
|
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette] | ||
B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette] | ||
B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: ALBANY MOLECULAR RESEARCH, INC. (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 15A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2330 DE 01-09-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |